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ABSTRACT 24 
A calf tissue cage model was used to study the pharmacokinetics (PK) and 25 
pharmacodynamics (PD) of oxytetracycline in serum, inflamed (exudate) and non-inflamed 26 
(transudate) tissue cage fluids. After intramuscular administration, the PK was characterised 27 
by a long mean residence time of 28.3h. Based on Minimum Inhibitory Concentrations 28 
(MICs) for six isolates each of Mannheimia haemolytica and Pasteurella multocida, 29 
measured in serum, integration of in vivo PK and in vitro PD data established area under 30 
serum concentration-time curve (AUC0-∞)/MIC ratios of 30.0 and 24.3h for M.haemolytica 31 
and P.multocida, respectively. Corresponding AUC0-∞/MIC ratios based on MICs in broth 32 
were 656 and 745h, respectively. PK-PD modelling of in vitro bacterial time-kill curves for 33 
oxytetracycline in serum established mean AUC0-24h/MIC ratios for 3log10 decrease in 34 
bacterial count of 27.5h (M.haemolytica) and 60.9h (P.multocida). Monte Carlo simulations 35 
predicted target attainment rate (TAR) dosages. Based on the potency of oxytetracycline in 36 
serum, the predicted 50% TAR single doses required to achieve a bacteriostatic action 37 
covering 48h periods were 197mg/kg (M.haemolytica) and 314mg/kg (P.multocida) 38 
respectively, against susceptible populations. Dosages based on the potency of 39 
oxytetracycline in broth were 25- and 27-fold lower (7.8 and 11.5mg/kg) for M.haemolytica 40 
and P.multocida, respectively.  41 
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INTRODUCTION  46 
 47 
The spectrum of activity of oxytetracycline includes two major bacterial species causing 48 
bovine pneumonia, Mannheimia haemolytica and Pasteurella multocida (Nouws et al., 1985; 49 
Nouws et al., 1985; Nouws et al., 1990).  Oxytetracycline remains in extensive use for the 50 
treatment of calf pneumonia as it possesses the advantage of availability in both low (5-51 
10%w/v) and high (20-30%w/v) strength injectable products. The latter provide high dose 52 
(20-30mg/kg) long acting formulations; single dose therapy may be clinically effective when 53 
these formulations are administered intramuscularly. These depot formulations provide 54 
sustained absorption from the intramuscular injection site, leading to flip-flop 55 
pharmacokinetics (PK) (Nouws & Vree, 1983; Toutain & Raynaud, 1983; Nouws et al., 56 
1990).  57 
Dosages for oxytetracycline were set many years ago and it may now be appropriate to re-58 
evaluate them in light of currently accepted PK/pharmacodynamic (PD) concepts. 59 
Scientifically, the soundest approach to prediction of dosage for antimicrobial drugs (AMDs) 60 
is to link PK parameters and variables with an appropriate PD index of potency and efficacy, 61 
applying the universal equation for systemically acting drugs:  62 
 𝐷𝑜𝑠𝑒 =
𝐶𝑙  ×  𝐴𝑈𝐶
𝐹
 (1) 63 
Where Dose is the computed dose, Cl=body clearance, F=bioavailability and AUC=area 64 
under plasma/serum concentration-time curve (Toutain & Bousquet-Melou, 2004). For those 65 
AMDs for which the PK/PD index that best predicts efficacy is AUC0-24h/MIC, such as 66 
oxytetracycline in the present investigation (see Results and Discussion), this equation was 67 
adapted by Aliabadi & Lees (2001; 2002) and Toutain & Lees  to: 68 
 𝐷𝑜𝑠𝑒(𝑝𝑒𝑟 𝑑𝑎𝑦) =  
𝐶𝑙  ×   
𝐴𝑈𝐶(0−24ℎ)
𝑀𝐼𝐶𝑒
   ×  𝑀𝐼𝐶𝑑𝑖𝑠𝑡𝑟𝑖𝑏𝑢𝑡𝑖𝑜𝑛
𝑓𝑢   ×   𝐹
 (2) 69 
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where Cl=body clearance per h, AUC0-24h/MICe (in h) = in vitro ratio of experimentally 70 
determined area under the serum or broth concentration-time curve over 24h to the Minimum 71 
Inhibitory Concentration (MICe) of the tested experimental isolates for a target end-point 72 
(bacteriostatic or bactericidal effect), MICdistribution=distribution of MICs of oxytetracycline 73 
from an epidemiological literature survey, fu (from 0 to 1)=fraction of drug not bound to 74 
serum protein and F=bioavailability (from 0 to 1). MIC distributions for P.multocida (498 75 
strains) and M.haemolytica (481 strains) were obtained from infected cattle; MICs were 76 
measured at the Iowa state Veterinary Diagnostic Laboratory Data from 2000, 2001, 2002 77 
and 2003 (http://vads.vetmed.vt.edu/index.cfm). From this, it is clear that selection of an 78 
optimal dose depends on: (1) assessment of both PK (Cl, F, fu,) and PD (MIC) properties; and 79 
(2) determination of an appropriate breakpoint value of the AUC0-24h/MIC ratio for 80 
bacteriostatic or bactericidal effect.  81 
The internationally accepted European Union Committee on Antimicrobial Testing 82 
(EUCAST) and the Clinical Laboratory Standards Institute  (CLSI, 2004; CLSI, 2008) 83 
methods for MIC determinations are based on the use, almost universally, of non-biological 84 
growth media, such as Mueller Hinton Broth (MHB) (Papich, 2013; Papich, 2014). Whilst 85 
such media are specifically formulated to provide optimal in vitro growth conditions, they 86 
differ in composition from body fluids. For example, most broths contain small amounts of 87 
protein including negligible amounts of albumin, whereas treatment of disease in vivo 88 
depends on drug concentration in the biological fluid of the biophase. Concentration in the 89 
latter is driven by the plasma concentration of free drug. As the protein bound fraction is 90 
microbiologically inactive, it is common to link the free rather than total serum concentration 91 
with an in vitro MIC (or MBC) value (fu in equation 2). A potential problem with this 92 
approach is the assumption that the differences in MIC determined in broth, serum and the 93 
local biophase milieu are attributable solely to drug protein binding in the latter two fluids. It 94 
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is potentially flawed additionally, because artificial broths are quantitatively dissimilar to 95 
biological fluids in most chemical constituents (not only albumin, to which most drugs bind 96 
to some degree) and also in the absence of proteins such as serum complement, which may 97 
impact on drug potency. Therefore, bacterial growth and AMD action may commonly differ 98 
in differing growth matrices. 99 
For the foregoing reasons, experiments in our laboratory have routinely compared MIC and 100 
MBC for calf pathogens in broth and biological fluids (serum, transudate and inflammatory 101 
exudate) obtained from calves, to provide more biologically relevant growth matrices and to 102 
identify any possible matrix effect (Aliabadi & Lees, 2002; Aliabadi et al., 2003; Sidhu et al., 103 
2010; Brentnall et al., 2012). The latter group reported that protein concentrations in exudate 104 
(44.7 g/L) and transudate (40.7 g/L) were lower than in calf serum (61.9 g/L). For example, 105 
for tulathromycin and the bovine pneumonia pathogens, M.haemolytica and P.multocida, 106 
serum:broth MIC ratios were of the order of 1:50, despite some 40% binding to serum protein 107 
(Illambas et al., 2009). In stark contrast, for a single strain of M.haemolytica, oxytetracycline 108 
MICs (µg/mL) were higher in serum (14.8) exudate (12.8) and transudate (11.2) than in MHB 109 
(0.5) (Brentnall et al., 2012). These marked differences between artificial broth and biological 110 
fluids are both drug and microbial species dependent and cannot be explained by binding to 111 
plasma protein.  112 
Determination of PD properties of oxytetracycline in biological matrices is therefore a pre-113 
requisite for the use of PK-PD integration and modelling approaches to dose determination, 114 
aimed at eradication of bacteria and/or minimising opportunities for the emergence of 115 
antimicrobial resistance  (Lees et al., 2004; Martinez & Silley, 2010; Mouton et al., 2011; 116 
Papich, 2014). For other drugs, smaller broth serum differences in potency have been 117 
reported, but it should be noted that a difference in MIC, between serum and broth, generally 118 
regarded as small in microbiological terms, could readily lead, when the objective is 119 
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prediction of dosage for bacteriological cure in diseased animals, to significant over or under 120 
estimation of dose required.  121 
Three integrated PK-PD surrogates for clinical efficacy; maximum serum concentration 122 
(Cmax)/MIC, time of serum concentration exceeding MIC (T>MIC) as a percentage of the 123 
inter-dose interval, and area under curve (AUC)/MIC, the ratio of the area under the 124 
plasma/serum concentration-time curve to MIC (in steady-state conditions) have been widely 125 
used (Craig, 1998; Schentag, 2000; Frimodt-Moller, 2002; Lees & Shojaee Aliabadi, 2002; 126 
Mouton et al., 2002; Toutain et al., 2002; Toutain & Lees, 2004; Martinez & Silley, 2010; 127 
Mouton et al., 2011; Martinez et al., 2012; Papich, 2014). This study focusses on AUC/MIC, 128 
as oxytetracycline has a long terminal half-life and it was shown that this index is the most 129 
appropriate for any AMD having a long terminal half-life (Nielsen & Friberg, 2013).   130 
The objectives of this investigation were: (1) to establish the serum concentration-time profile 131 
and to derive PK data for oxytetracycline in 10 healthy calves after intramuscular 132 
administration at the dose rate of 20mg/kg; (2) to determine the rate and extent of 133 
oxytetracycline penetration into and elimination from carrageenan-inflamed (exudate) and 134 
non-inflamed (transudate) fluids in a tissue cage model; (3) to integrate these in vivo PK 135 
findings with in vitro PD (MIC) data for oxytetracycline against M.haemolytica and 136 
P.multocida; (4) to model in vitro time-kill profiles of oxytetracycline against six isolates 137 
each of M.haemolytica and P.multocida in both serum and MHB, in order to generate 138 
AUC/MIC breakpoints for each organism to achieve bacteriostatic and bactericidal levels of 139 
growth inhibition; (5) to use the derived PK and PD data, with epidemiological MIC 140 
distributions, to calculate, using Monte Carlo simulations, dosages of oxytetracycline for both 141 
an empirical (probabilist) therapeutic response i.e. taking into account the entire MIC 142 
distribution but also considering only susceptible subpopulations of P.multocida and M. 143 
haemolytica. Such dual simulations are necessary to investigate the clinical value of an 144 
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antimicrobial sensitivity test (AST) and also to determine its appropriate numerical value. 145 
Simulations were undertaken for: (a) each bacterial species; (b) two levels of growth 146 
inhibition (bacteriostatic and bactericidal); and (c) both a single dose (efficacious over the 147 
subsequent 48h) and a maintenance dose administered every 48h under steady-state 148 
conditions for 50 and 90% Target Attainment Rates (TARs).   149 
 150 
MATERIALS AND METHODS 151 
Animals and surgical procedures 152 
An in vivo study was conducted in 10 healthy female Aberdeen Angus calves.  Weights were 153 
in the range 145-204kg (mean=179kg, S.D.=16.7) and ages ranged from 79-131 days (mean 154 
=108, S.D.=15 days). Tissue cages were implanted subcutaneously in the paralumbar fossa, 155 
as previously described (Sidhu et al., 2003).  Oxytetracycline hydrochloride (Alamycin LA, 156 
Norbrook Laboratories Ltd., Newry, Co. Down, N. Ireland) was injected intramuscularly into 157 
gluteal muscles (two equal volumes into right and left muscles) at a dose rate of 20mg/kg at 158 
zero time. Also at zero time, 0.5mL of 1%w/v sterile lambda carrageenan solution in saline 159 
(Viscarin, Marine Colloids, Springfield, U.S.A.) was injected into a single tissue cage. This 160 
was used to harvest inflammatory exudate. A second, unstimulated cage was used to collect 161 
non-inflammatory extracellular fluid (transudate). The study was approved by the Royal 162 
Veterinary College Ethics Committee. 163 
 164 
Sampling procedures 165 
Blood samples (10mL) were collected, protected from light, from a jugular vein, into 166 
vacutainers (Becton, Dickinson and Company, Oxford, Oxon, U.K.) without anticoagulant, 167 
prior to and at times of 15, 30 and 45min and 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 32, 48, 72, 96 and 168 
120h after injection of oxytetracycline. Exudate and transudate samples (1.5mL) were 169 
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collected, protected from light, before and at pre-determined times of 2, 4, 6, 8, 10, 12, 24, 170 
32, 72, 96 and 120h. All samples were centrifuged to remove cells at 2,000g for 10min at 4°C 171 
and supernatants were stored at -70°C until analysed for oxytetracycline. 172 
 173 
Analysis of oxytetracycline  174 
A high pressure liquid chromatography (HPLC) method with ultraviolet detection was used 175 
for analysis of oxytetracycline concentrations in serum, exudate and transudate (Brentnall et 176 
al., 2012). All reagents were HPLC grade and obtained from Sigma-Aldrich Chemicals 177 
(Poole, Dorset, UK). Chromatographic data were analysed using ChromeleonTM Version 6.80 178 
(Dionex Corporation) and concentrations of oxytetracycline were calculated using peak area 179 
ratios. Standards were prepared by spiking blank serum, exudate and transudate with 180 
oxytetracycline, using eight concentrations over the range 0.1 to 25µg/mL (serum) and 0.1 to 181 
5µg/mL (exudate and transudate). They were run with every assay to evaluate linearity and 182 
reproducibility. For linearity r2 was >0.98. The lower limit of quantification (LLOQ) for 183 
oxytetracycline in all three fluids was 0.1µg/mL. The LLOQ had a coefficient of variation of 184 
less than 20% and all other standards were less than 15% of nominal concentration. The intra- 185 
and inter-assay percentage inaccuracies were 3.50% and 9.57%, respectively, at a 186 
concentration of 10µg/mL, 1.43% and 4.78%, respectively, at a concentration of 5µg/mL and 187 
2.06% and 10.6%, respectively, at a concentration of 0.1µg/mL.  188 
 189 
Pharmacokinetic analyses 190 
Oxytetracycline concentration-time data in serum, exudate and transudate in individual calves 191 
were analysed using the WinNonlin® regression programme (version 5.2, Pharsight 192 
Corporation, Mountain View, California, USA). Data for each fluid were submitted to non-193 
compartmental analysis using the statistical moment approach described by (Yamaoka et al., 194 
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1978). The linear trapezoidal rule was used to calculate AUC values and area under the first 195 
moment curve (AUMC).  The mean residence time (MRT) was determined as AUMC/AUC. 196 
 197 
PK-PD integration 198 
The PK-PD surrogates Cmax/MIC, AUC0-24h/MIC (first 24h after dosing) and AUC0-∞/MIC 199 
were calculated for each fluid (serum, exudate and transudate) harvested in the tissue cage 200 
study from 10 calves. Results were expressed as ratios of geometric mean Cmax, AUC0-24h and 201 
AUC0-∞ for individual calves (n=10) and geometric mean MIC (n=6 for each bacterial 202 
species). Geometric means were selected for measurements which are lognormally 203 
distributed. In addition, the ratios of average serum concentration (Cav)/MIC, for four 204 
consecutive 24h periods after administration of oxytetracycline, were calculated. 205 
 206 
PK-PD modelling of in vitro time-kill data 207 
For six isolates each of M.haemolytica and P.multocida growth inhibition curves over 24h 208 
were determined in two matrices, MHB and calf serum, as previously described (Lees et al., 209 
2015). Ratios of AUC0-24h/MIC were calculated for each of the six isolates of the two 210 
organisms at each of the five oxytetracycline concentrations tested (from 0.25 to 4xMIC 211 
multiples). AUC0-24h values were computed in terms of MIC multiples (vide infra). The data 212 
were modelled to the sigmoidal Emax equation (Equation 3) using the non-linear regression 213 
WinNonlin® programme:  214 
 𝐸 =  𝐸0 +  
𝐸𝑚𝑎𝑥 ×  𝑋
𝑁 
𝐸𝐶50
𝑁  +  𝑋𝑁
. (3) 215 
where E0 is the bacterial growth after 24h incubation in the absence of oxytetracycline 216 
(control samples), expressed as log10cfu/mL subtracted from the initial inoculum log10 217 
cfu/mL; Emax is the maximum antimicrobial growth inhibition determined as the change in 218 
log10cfu/mL after 24h incubation with oxytetracycline; EC50 is the AUC0-24h/MIC value 219 
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providing 50% of the maximum antibacterial effect; X is the predictive variable (expressed as 220 
AUC0-24h/MIC) and N is the Hill coefficient, which describes the slope of the AUC0-24h/MIC-221 
effect curve. Bacteriostatic (E=0, no change form initial inoculum count), bactericidal (E=-3, 222 
a 3log10 reduction from initial inoculum count) and E=-4, a 4log10 reduction from initial 223 
inoculum count AUC0-24h/MIC values, were determined for each isolate of each organism in 224 
MHB and serum. E=-4, a 4log10 reduction in count, represents a 10,000-fold decrease from a 225 
starting count of 107 cfu/mL to a count of 103 cfu/mL; therefore it does not indicate virtual 226 
eradication. 227 
The AUC0-24h/MIC values are proportionality factors between the MIC of the test pathogen 228 
(i.e. AUC/MICe in equation 2) and the average MHB or serum oxytetracycline concentration 229 
required to achieve each level of growth inhibition. From the AUC0-24h/MIC values, the 230 
average concentrations corresponding to the three levels of kill over 24h were calculated and 231 
expressed as multiples of MIC by dividing each value of AUC0-24h/MIC by 24h (Toutain et 232 
al., 2007). 233 
 234 
Dosage prediction using Monte Carlo simulations  235 
 General principles  236 
Equation 1 (see Introduction) is the general equation used to determine dosage for 237 
systemically acting drugs. For those AMDs, for which the PK-PD index that best predicts 238 
efficacy is AUC0-24h/MIC, such as oxytetracycline in the present investigation, this equation 239 
was adapted to Equation 2 (see Introduction).  240 
 Dosage determination using a steady state approach (48h dosing interval)  241 
In Equation 2, the term AUC0-24h/MIC (h) is the experimentally determined PK-PD index to 242 
be achieved, expressed as the ratio of area under the serum concentration-time curve over 24h 243 
to MIC, obtained using a test pathogen for a given bacteriological effect (bacteriostatic, 244 
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bactericidal or 4log10 reduction in count). For greater clarity, we replaced the AUC0-24h/MIC 245 
ratio in h, by a more readily understood dimensionless equivalent PD factor: κPD, (Toutain et 246 
al., 2007). κPD is obtained by dividing AUC0-24h/MIC in h by 24h and this requires, for 247 
consistency, serum clearance to be expressed per day (Clday) where Clday=24h x Cl expressed 248 
per h as for equation 2, when the computed dose is a daily dose. Hence, κPD represents the 249 
scaling factor by which the clinical MIC (or any MIC from the MIC distribution) should be 250 
multiplied to obtain the appropriate serum concentration to be achieved for a given PD effect 251 
(bacteriostatic, bactericidal or 4log10 reduction in count). When κPD is substituted in Equation 252 
2, it yields: 253 
 𝐷𝑜𝑠𝑒(𝑚𝑎𝑖𝑛𝑡𝑒𝑛𝑎𝑛𝑐𝑒 𝑝𝑒𝑟 𝑑𝑎𝑦) =   
𝐶𝑙𝑑𝑎𝑦    × Κ𝑃𝐷  ×  𝑀𝐼𝐶𝑑𝑖𝑠𝑡𝑟𝑖𝑏𝑢𝑡𝑖𝑜𝑛.
𝐹                  ×                       𝑓𝑢      
 (4) 254 
where Dose(maintenance per day) is a daily maintenance dose in steady-state equilibrium conditions.  255 
The expression can be extended to time intervals longer than 24h (Toutain et al., 2007). For 256 
the long-acting formulation of oxytetracycline used in this study, with a recommended 257 
interval of 48h between two doses at steady-state, Clday is substituted in equation 5 by Cl48h 258 
(where Cl48h = 48h x Cl expressed per h as for equation 2).  259 
 𝐷𝑜𝑠𝑒(𝑚𝑎𝑖𝑛𝑡𝑒𝑛𝑎𝑛𝑐𝑒 𝑝𝑒𝑟 48ℎ) =   𝐶𝑙(48ℎ)  ×
 Κ𝑃𝐷  ×  𝑀𝐼𝐶𝑑𝑖𝑠𝑡𝑟𝑖𝑏𝑢𝑡𝑖𝑜𝑛
𝐹           ×           𝑓𝑢      
 (5) 260 
 261 
 Dosage determination for a single dose (active over the first 48h period) 262 
It is relevant, for a long-acting formulation, to estimate the single dose required to achieve 263 
bacteriostatic, bactericidal and 4log10 reductions in count over the first dosage interval (in this 264 
case 48h) i.e. before reaching steady-state conditions, if achieved. This first dose is a loading 265 
dose, whilst the dose computed by equation 5 is a maintenance dose. The ratio between the 266 
loading dose and the maintenance dose is equal, by definition, to the accumulation ratio and 267 
for the present formulation is indicated by equation 6 (Toutain & Bousquet-Mélou, 2004): 268 
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 𝑅 =   
𝐴𝑈𝐶(𝑙𝑜𝑎𝑑𝑖𝑛𝑔 𝑑𝑜𝑠𝑒)
  𝐴𝑈𝐶(𝑚𝑎𝑖𝑛𝑡𝑒𝑛𝑎𝑛𝑐𝑒 𝑑𝑜𝑠𝑒)    
 (6) 269 
Assuming that administration of the dose n+1 occurs at a time after which the distribution of 270 
the previous dose n is complete (pseudo-steady state) the accumulation ratio can be 271 
simplified as per equation 7: 272 
 𝑅 =  
1
1− exp (−𝐾10×𝜏)
  (7) 273 
with k10 expressed in h
-1 and τ is the dosing interval in h. Therefore, R is dimensionless. For 274 
further explanation see Lees et al. (Lees et al., 2015). Combining equations 6 and 7 and 275 
assuming PK linearity (clearance identical with two dose levels), the loading dose for 48h 276 
effect for the ith calf Dosei(loading dose) is calculated from equation 8: 277 
 Dose(loading dose 48h) =  
1
1 −  exp (−𝐾10 × 𝜏)
 ×  Dose(maintenance per 48h) 278 
i.e. 279 
Dose(loading dose 48h) =  
1
1− exp (−𝐾10×48)
×  𝐶𝑙(48ℎ)  ×
 Κ𝑃𝐷  ×  𝑀𝐼𝐶𝑑𝑖𝑠𝑡𝑟𝑖𝑏𝑢𝑡𝑖𝑜𝑛
𝐹           ×           𝑓𝑢      
  (8) 280 
 281 
 Monte Carlo simulation for the two approaches to dose estimation: 282 
Dosages were computed using Monte Carlo simulations in Oracle Crystal Ball (Oracle 283 
Corporation, Redwood Shores, CA, USA). The maintenance dose (per 48h) was calculated 284 
using equation (5) and the loading dose (for 48h interval) was calculated using equation 8. 285 
Loading and maintenance doses were determined to achieve bacteriostatic and bactericidal 286 
responses. The probabilistic approach took into account the different distribution of variables 287 
embedded in Equations 5 and 8. The average point estimate of the serum κPD was calculated 288 
from the data obtained with four isolates of each species, but variability in κPD was not 289 
included in the Monte Carlo simulation, as the number of isolates was small and inter-isolate 290 
variability was low. The distribution of individual plasma clearances within the sample 291 
population (10 calves in the present study) was included for calculation of the maintenance 292 
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dose (Equation 5). The observed statistical distribution of products of individual serum 293 
clearance by individual accumulation ratio for a 48h dosing interval (determined by 294 
individual k10 values) was incorporated for calculation of the loading dose (Equation 8).  295 
The distribution of field MIC values for M.haemolytica and P.multocida (considered 296 
separately) were included in the simulation. MICdistribution is the MIC for M.haemolytica (481 297 
isolates) and P.multocida (498 isolates); these were published online by the Iowa State 298 
Veterinary Diagnostic Laboratory data (2000-2003) and are represented in Fig. 2a and 2b. 299 
These distributions reflect the current U.S.A. situation and prompted us to determine the 300 
corresponding susceptible wild-type population; the latter is expected to be the same 301 
throughout the world, see Discussion). This wild-type distribution was statistically 302 
determined by calculation of the 99.9% wild-type cut-off values plotted in Fig. 2c and 2d 303 
(Turnidge et al., 2006). Only the MIC distribution of wild type bacteria was included in the 304 
simulation, corrected by the experimentally determined value of fu to allow for 305 
oxytetracycline protein binding in serum, as the reported MIC literature values were 306 
determined in broth. A further correction factor was applied to account for MIC differences 307 
between broth and serum for both species. The probabilities of distribution for each dosage 308 
estimation were run for 50,000 simulated trials. 309 
Figure 1 310 
Statistical analyses 311 
PK variables are presented as geometric, harmonic or arithmetic means and SD. MIC and 312 
MBC data are presented as geometric means and SD. Differences in MIC and MBC values 313 
between MHB and serum were compared with the paired t-test or the non-parametric 314 
Wilcoxon test, depending on whether the data passed a normality test. Mean differences in 315 
AUC0-24h/MIC ratios determined in MHB compared with those determined in serum for 316 
bacteriostatic, bactericidal and 4log10 reductions in count were compared by ANOVA.  317 
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 318 
RESULTS 319 
Pharmacokinetics 320 
The mean (±SEM) concentrations of oxytetracycline in calf fluids after intramuscular 321 
administration at a dose rate of 20mg/kg are presented in Fig. 2. PK variables are presented in 322 
Table 1. In 6 of 10 calves the serum concentration-time profile was characterised by two 323 
peaks, the first occurring within 1h and the second between 1.5 and 4h. 324 
Oxytetracycline penetration into exudate and transudate was quantitatively similar. Exudate 325 
and transudate Cmax were significantly lower than peak serum concentration (P<0.01). 326 
However, from 32 to 120h oxytetracycline concentrations in tissue cage fluids were greater 327 
than those in serum (Fig.1). Numerically lower AUC0-last values were obtained in exudate and 328 
transudate, 125µg.h/mL and 105µg.h/mL, respectively, compared to 153µg.h/mL in serum, 329 
but these differences were not statistically significant (P>0.05). For all three fluids, the 330 
percentage of AUC0-∞ occurring after the last sampling time (120h) was <12%.  Mean 331 
residence times were similar in exudate and transudate and both were significantly longer 332 
(P<0.01) than MRT in serum (Table1).   333 
Table 1 334 
Fig.2 335 
PK-PD integration 336 
PK-PD integration established the surrogates, Cmax/MIC,  T>MIC,  AUC0-24h/MIC (first 24h) 337 
and AUC0-∞/MIC, derived from in vivo oxytetracycline serum concentrations in the PK study 338 
and in vitro MICs of the test organisms measured in both MHB and serum. Data are 339 
presented in Appendix 1.  340 
Average oxytetracycline concentrations (Cave) in serum in the PK study, over four successive 341 
24h time periods, from 0-24 to 72-96h, were determined. Based on MHB MICs, Cave/MIC 342 
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ratios exceeded 1.5:1 up to 72-96h, whereas based on serum MICs the ratios were less than 343 
1:1 for all four time intervals (Table 2). Ratios of oxytetracycline Cave in exudate and 344 
transudate relative to mean MICs for M.haemolytica and P.multocida over each of the five 345 
successive time periods, from 0-24 to 96-120h, were greater than 1:1 for all periods based on 346 
MHB MICs but less than 0.4:1 for all periods based on serum MICs (data not shown).  347 
Table 2 348 
PK-PD modelling and dosage determination 349 
Time-kill curves for oxytetracycline for six isolates each of M.haemolytica and P.multocida 350 
were determined in MHB and calf serum (data reported in Lees et al., 2016a). The killing 351 
patterns were judged to be co-dependent. Values of AUC0-24h/MIC producing three levels of 352 
bacterial kill [bacteriostatic, 3log10 reduction (bactericidal) and 4log10 reduction from initial 353 
inoculum count] were determined for both MHB and serum (Tables 3 and 4). For 354 
M.haemolytica 3 or 4log10 reductions in count were not obtained for all isolates (Table 3). 355 
Mean AUC0-24h/MIC serum values (with AUC0-24h expressed in terms of multiple of MIC for 356 
a given matrix and the MIC of the test bacteria for the same matrix) producing bacteriostatic 357 
and bactericidal responses for M.haemolytica were 19.1 and 27.5h, respectively, 358 
corresponding to average concentrations over 24h incubation (κPD  values) of 0.79 and 1.15 359 
multiples of MIC for the given matrix (Toutain et al., 2007). Corresponding AUC0-24h/MIC 360 
and κPD values using MHB as growth medium were 25.2 and 46.0h and 1.05 and 1.92, 361 
respectively. For both matrices and both pathogens, bacteriostatic and bactericidal effects 362 
were obtained with concentrations of the same order of magnitude and observed differences 363 
are likely due to the limited precision of the killing curve measurements. 364 
Tables 3 and 4 365 
Predicted doses for both single dose administration and dosing at steady state are presented in 366 
Table 5. For single administration (duration of action of 48h), the Monte Carlo derived doses 367 
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for TARs of 50 and 90% providing a bacteriostatic action against M.haemolytica were 197 368 
and 283 mg/kg, respectively, based on serum MICs of the sensitive population (Table 5). 369 
However, based on broth MICs, corresponding values were much lower, 7.81 and 11.24 370 
mg/kg (Appendix 2). Higher dosages were required for TARs to provide a bactericidal level; 371 
for MICs determined in serum 50 and 90% TARs were 314 and 452 mg/kg, respectively. 372 
For P.multocida and a bacteriostatic action with single dose administration and a duration of 373 
action of 48h, 50 and 90% TARs were 314 and 682 mg/kg, based on serum MICs (Table 5). 374 
However, based on broth MICs corresponding values were much lower, 11.5 and 24.9 mg/kg 375 
(Appendix 2). As for M.haemolytica, for a bactericidal action, higher doses were predicted.  376 
As expected from the accumulation ratio over a dosing interval of 48h (approximately 1.5-377 
1.6), the predicted alternate day doses, at steady state, were lower than those calculated for 378 
the single dose approach. Thus, based on serum MICs and a bacteriostatic action, TARs of 50 379 
and 90% were 125 and 141 mg/kg for M.haemolytica and 200 and 424 mg/kg for P.multocida 380 
(Table 5). Much lower doses were predicted for alternate day administration at steady state 381 
based on broth MICs. Predicted doses were 4.97 and 5.58 mg/kg for M.haemolytica for 50 382 
and 90% TARs for bacteriostasis. Corresponding predicted doses were 7.28 and 15.4 mg/kg 383 
for P.multocida (Appendix 2).   384 
Table 5 385 
 386 
DISCUSSION 387 
Pharmacokinetics 388 
Tissue cages comprise hollow perforated devices, which become surrounded by and partially 389 
infiltrated with granulation tissue, when implanted subcutaneously (Higgins et al., 1984; Lees 390 
et al., 1987). When using tissue cages to study the extravascular distribution of drugs, it is 391 
important to recognise that the time courses of penetration into and removal from tissue cage 392 
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fluid are model (shape) dependent.  Thus, solute (including drug) penetration and elimination 393 
rates vary with each drug/solute, tissue cage age, size, location and geometry, most notably 394 
with surface area:volume ratio of the cage.   395 
Intracaveal injection of the mild irritant carrageenan provides an ethical means of generating 396 
and readily sampling inflammatory exudate (Lees et al., 1987; Sidhu et al., 2003). The tissue 397 
cage model therefore provides a mean of studying a possible matrix effect when investigating 398 
ex vivo PD of AMDs not only in serum (which is not the ultimate site of AMD action) but 399 
also in matrices that better reflect composition of the AMD biophase for extracellular 400 
pathogens namely exudate (in the presence of inflammation as appropriate for curative 401 
treatment) and transudate (in the absence of inflammation as appropriate for prophylaxis and 402 
for metaphylaxis) (Aliabadi et al., 2003; Sidhu et al., 2010; Brentnall et al., 2012). The tissue 403 
cage model thus facilitates comparison of PD data with findings generated in non-biological 404 
growth matrices, such as MHB.  405 
The serum concentration-time profile of oxytetracycline, using a high strength depot 406 
formulation, was similar to those reported in earlier studies with the same dose rate of 20 407 
mg/kg administered intramuscularly (Nouws & Vree, 1983; Toutain & Raynaud, 1983; 408 
Davey et al., 1985; El Korchi et al., 2001; Mestorino et al., 2007; Brentnall et al., 2012). 409 
Toutain and Raynaud (1983) reported that oxytetracycline absorption occurred in two phases; 410 
the first was rapid and the second slower phase led to a flip-flop PK profile. The findings in 411 
this study, likewise, indicated rapid initial absorption and, in most animals, two early 412 
concentration peaks. It is very likely that, as in previous studies, the PK profile was flip-flop, 413 
with slow passage of the drug into solution at the injection site (Nouws et al., 1990). Thus, in 414 
the previous studies and the present investigation, the terminal half-life, representing a slow 415 
absorption phase, was prolonged, ranging from 21.7h (Brentnall et al., 2012) to 30.1h (this 416 
investigation).   417 
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 418 
PK-PD integration 419 
The underlying cause(s) of marked serum/MHB differences in potency of oxytetracycline, as 420 
reflected in MICs, have not been established.  Approximately two-fold higher MICs in serum 421 
compared to MHB would be anticipated from the binding of oxytetracycline to serum 422 
proteins, which was shown to be 53% of total concentration in calves (Lees et al., 2016). This 423 
is well short of the approximately 25-fold differences in MIC obtained experimentally (Lees 424 
et al., 2016). Serum/MHB MIC (µg/mL) ratios were 6.75/0.25 (P.multocida) and 5.46/0.22 425 
(M.haemolytica). 426 
Mean serum MIC of M.haemolytica in this study was 5.46µg/mL. Esaki et al. (2005) reported 427 
MIC50 and MIC90 values, in broth, of 0.25 and 32µg/mL for oxytetracycline against 27 428 
bovine strains of M.haemolytica.  If MICs of these strains in serum had been 25 times greater 429 
than in artificial growth media (as for the six strains used in this investigation), the 430 
corresponding predicted MICs would be 6.3µg/mL (MIC50) and 800 µg/mL (MIC90). 431 
Similarly, in the data from Iowa State University, broth MICs were ≥8µg/mL for 50% of 432 
M.haemolytica and 38% of P.multocida isolates; applying the 25-fold broth/serum scaling 433 
factor equates to >200µg/mL for a significant proportion of field isolates.   434 
  435 
The most appropriate PK/PD index to correlate with clinical efficacy depends on AMD 436 
terminal half-life; when this is relatively long, as for oxytetracycline in this study, AUC/MIC 437 
ratio is the index of choice (Nielsen & Friberg, 2013). From the present data, the predicted 438 
clinical efficacy of oxytetracycline in vivo would be at most slight, insofar as it depends on 439 
both serum MIC and a direct inhibitory action on cell division.  This conclusion was 440 
confirmed in a previous study by ex vivo findings; time-kill curves obtained with near 441 
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maximum oxytetracycline concentrations in serum produced little or no growth inhibition of 442 
M.haemolytica and P.multocida isolates (Lees et al., 2016).   443 
 444 
PK/PD modelling 445 
For both M.haemolytica and P.multocida a bacteriostatic action was achieved with AUC0-446 
24h/MIC values in the range 19.1 to 28.0h in both MHB and serum. Breakpoint AUC0-447 
24h/MICe values for a bactericidal action were 46.1h (MHB) and 27.5h (serum) for 448 
M.haemolytica and 25.8h (MHB) and 60.9h (serum) for P.multocida. Also of potential 449 
clinical significance is the inter-isolate within-species variability in breakpoint values, which 450 
was greater for M.haemolytica than P.multocida. However, these differences, for a small 451 
number of isolates, remain to be confirmed with more isolates in future studies and were not 452 
taken into account in our Mont Carlo simulations. 453 
 454 
Dosage prediction  455 
Predicted (TAR) doses for oxytetracycline were calculated using scientific literature values 456 
for oxytetracycline MIC distributions together with data from this study for PK variables 457 
(Cl/F and fu) and PK-PD breakpoints (AUC0-24h/MICe). Fifty and 90% TAR dosages were 458 
calculated for steady state and for single doses with a duration of action of 48h in both cases. 459 
All doses based on oxytetracycline MICs in serum were some 25-fold greater than doses 460 
based on MICs measured by the CLSI method in broth. For example, for single dosing and a 461 
period of 48h the 90% TAR dosages for a bactericidal action (serum first, broth second) were 462 
452 and 17.9 mg/kg (M.haemolytica) and 1,523 and 55.6 mg/kg (P.multocida).  463 
Despite these considerations, it should be noted that oxytetracycline is usually classified as a 464 
bacteriostat and it is therefore assumed that efficacy will generally require the support of the 465 
body’s natural defence mechanisms. Moreover, the challenge presented to the killing action 466 
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of oxytetracycline in our time-kill experiments, with a starting inoculum count of the order of 467 
107cfu/mL, may be described as heavy, in comparison with bacterial load in clinical subjects 468 
with natural infection. It is also approximately 100-fold higher than the inoculum count 469 
recommended for AMD PD studies by CLSI, the higher count being deliberately selected to 470 
represent a heavy load in this study. In those cases where infection is mild and treated early, 471 
when biophase bacterial counts would be predicted to be low, as discussed by Mouton et al. 472 
(2011), Martinez et al. (2012) and Papich (2013; Papich, 2014) lower doses of 473 
oxytetracycline are likely to suffice. Nevertheless, the calculated doses based on serum data 474 
were considerably higher than the recommended dose rate of 20 mg/kg oxytetracycline.  475 
These high dosages for both 50 and 90% TARs were calculated using the oxytetracycline 476 
epidemiological MIC distributions for P.multocida and M.haemolytica measured from 2000 477 
to 2003 and published on the Veterinary Antimicrobial Decision Support Website 478 
(http://vads.vetmed.vt.edu/index.cfm). Distributions were bimodal, with 39-50% of isolates 479 
having broth MICs of 8µg/mL or greater and 48-55% with MICs of 1µg/mL or less. This 480 
suggests that the wild-type populations for P.multocida and M.haemolytica are characterised 481 
by a MIC of approximately 1µg/mL or less. In this regard, the MICs of the related drug, 482 
tetracycline, are of interest. Isolates obtained from four USA and one Canadian regions, 483 
yearly over a 10 year period, had similar bimodal distributions for P.multocida and 484 
M.haemolytica, with MICs of the order of ≤1.0µg/mL for approximately 50% of isolates and 485 
≥8.0 µg/mL for some 30-50% of isolates (Portis et al., 2012).  486 
These data suggest that epidemiological information obtained for tetracycline might also be 487 
relevant for oxytetracycline. In this regard, de Jong et al. (de Jong et al., 2014) reported for 488 
EU tetracycline isolates essentially unimodal distributions for P.multocida and 489 
M.haemolytica of bovine origin; 94 and 84 % of isolates, respectively, had MICs of 2µg/mL 490 
or less, which is consistent with a wild type distribution for P.multocida and M.haemolytica . 491 
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This could be explained by the fact that these authors collected samples from diseased or 492 
recently deceased calves not exposed to AMD treatment for at least 15 days prior to sampling 493 
i.e. having not been subjected to any selective pressure with an enrichment of less susceptible 494 
pathogens to oxytetracycline. We are not aware of any recent data of EU origin for 495 
oxytetracycline against these species but EUCAST provides a cut-off value for 496 
M.haemolytica for tetracycline of 2µg/mL and the EUCAST distribution for oxytetracycline 497 
for P.multocida also suggests a cut-off of 2µg/mL. The MIC distribution of field strains 498 
represents isolates that might be submitted to the laboratory in cases of failure with first 499 
intention treatment and for this reason the Monte Carlo simulations were performed using 500 
only the wild type sub-population. It should be noted that Epidemiological Cut Off values are 501 
useful tools for epidemiologists but clinicians require clinical breakpoints. 502 
 503 
Clinical efficacy of oxytetracycline  504 
In early field studies, usually with small animal numbers, oxytetracycline was reported as 505 
effective for metaphylaxis and therapy in cases of calf pneumonia, as assessed by resolution 506 
or improvement of clinical signs (Laven & Andrews, 1991; Morck et al., 1993; Deleforge et 507 
al., 1994; Musser et al., 1996). On the other hand, O’Connor et al. (O'Connor et al., 2013) 508 
used a mixed treatment comparison meta-analysis to compare the efficacy of 12 AMD 509 
treatments versus a non-active control for bovine respiratory disease in beef cattle. They 510 
concluded that oxytetracycline had the lowest ranking (11.24 with a credibility interval of 9-511 
13) close to the ranking of the non-active control (12.52 with a credibility interval of 11-13).  512 
They also drew attention to the lack of recent data for oxytetracycline. 513 
These clinical findings and the present data focus consideration on possible mechanisms of 514 
action of oxytetracycline, in addition to its direct growth inhibiting action, as discussed 515 
previously (Brentnall et al., 2012; Lees et al., 2015). Drugs of the tetracycline group have 516 
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been shown to possess anti-inflammatory and host immune modulating actions, as well as 517 
reducing pathogen ability to attach to host cells Furthermore, in limited support of the 518 
20mg/kg dose of oxytetracycline, in a M.haemolytica-induced model of calf pneumonia, the 519 
bronchial secretion count of M.haemolytica was reduced from 4.106 to 1.103 cfu/mL at 48h 520 
and rectal temperature rise was decreased by 0.5°C, compared to nil treatment. However, 521 
oxytetracycline did not reduce the bacterial count in lung tissue.  522 
In summary, it is concluded, that oxytetracycline doses for a direct killing action, based on 523 
PK/PD relationships and using serum MIC data, are not achievable in clinical use. Moreover, 524 
it is unlikely that Antimicrobial Sensitivity Testing for this drug, against the calf pneumonia 525 
pathogens, M.haemolytica and P.multocida, can be used to predict clinical efficacy. 526 
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Table 1.  685 
Pharmacokinetic parameters for oxytetracycline in serum, exudate and transudate (geometric 686 
mean, unless stated, and SD, n=10)   687 
Variable 
(units) 
        Serum        Exudate    Transudate 
Mean SD Mean SD Mean SD 
Cmax (µg/mL) 5.23 0.61 2.20 0.31 2.09 0.38 
Tmax (h)* 3.60 0.84 11.6 0.84 10.99 1.93 
T½ (h)** 30.10 10.23 31.4 5.47 34.75 8.65 
AUC0-last (µg.h/mL) 153.2 17.22 125.2 21.22 105.24 16.05 
AUC0-∞ (µg.h/mL) 163.9 16.05 138.3 22.98 118.8 16.55 
AUC0-24 (µg.h/mL) 86.98 10.69 40.7 5.12 36.71 7.01 
AUC0-48 (µg.h/mL) 121.90 16.32 78.4 10.78 68.86 10.51 
MRT(0-last) (h)* 28.31 2.12 42.3 2.39 40.7 1.16 
Cl/F (mL/kg/h) 122.0 10.83 NA - NA - 
*Arithmetic mean **Harmonic mean 688 
Tmax: Time following dosing at which the maximum concentration (Cmax) occurred. 689 
T½: Half-life 690 
AUC0-last: Area under the concentration-time graph from 0 to the last sample 691 
AUC0-∞: Area under the concentration-time graph from 0 to infinity 692 
AUC0-24: Area under the concentration-time graph from 0 to 24h 693 
AUC0-48: Area under the concentration-time graph from 0 to 48h 694 
MRT: Mean residence time 695 
CI/F: Clearance scaled by bioavailability 696 
697 
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Table 2  698 
Average serum oxytetracycline concentration (Cave)/MIC ratios for four consecutive 24h 699 
periods after oxytetracycline administration (n=10 calves) 700 
              Cave/MIC 
Time period after dosing (h) 0-24 24-48 48-72 72-96 
 
P.multocida 
Based on mean serum MIC  
(6.75µg/mL) 
0.54 0.22 0.10 0.06 
Based on mean MHB MIC  
(0.25µg/mL) 
 
14.6 5.88 2.71 1.52 
 
M.haemolytica 
Based on mean serum MIC 
(5.46µg/mL) 
0.67 0.27 0.12 0.07 
Based on mean MHB MIC 
(0.22µg/mL) 
16.6 6.68 3.08 1.73 
  701 
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Table 3  702 
PK-PD modelling of in vitro time-kill data (mean and SD, n=6 unless stated) for three levels 703 
of growth inhibition of M.haemolytica by oxytetracycline in MHB and serum  704 
Variable MHB Serum 
Mean SD Mean SD 
Log Emax (cfu/mL) 
Log E0 (cfu/mL) 
Log Emax – log E0 (cfu/mL) 
AUC0-24h/MIC for bacteriostatic action (h) 
AUC0-24h/MIC for 3log10  count reduction (h) 
AUC0-24h/MIC for 4log10 count reduction (h) 
N (slope) 
-4.36 
1.73 
-6.10 
25.2 
46.0 
71.3* 
7.95 
0.97 
1.07 
0.70 
15.19 
22.76 
33.98 
6.05 
-5.08 
0.89 
-5.94 
19.1 
27. 5* 
N.D. 
8.17 
3.88 
0.91 
4.52 
18.30 
15.95 
- 
7.50 
*n=4;  ND=not determined 705 
  706 
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Table 4  707 
PK-PD modelling of in vitro time-kill data (mean and SD, n=6 unless stated) for three levels 708 
of inhibition of P.multocida by oxytetracycline in MHB and serum 709 
Measurement         MHB         Serum 
Mean SD Mean SD 
Log Emax (cfu/mL) 
Log E0 (cfu/mL) 
Log Emax – log E0 (cfu/mL) 
AUC0-24h/MIC for bacteriostatic action (h) 
AUC0-24h/MIC for 3log10  count reduction (h) 
AUC0-24h/MIC for 4log10 count reduction (h) 
N (slope) 
-5.48 
1.93 
-7.41 
19.2 
25.8 
30.2 
13.47 
1.00 
0.67 
0.69 
11.53 
10.75 
13.78 
8.08 
-4.35 
2.63 
-6.96 
28.0 
60.9* 
N.D. 
4.55 
1.98 
1.50 
2.42 
3.43 
12.65 
 
4.44 
*n=5; ND=not determined 710 
 711 
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Table 5.  713 
Predicted dosage (mg/kg) based on PK-PD modelling and Monte Carlo simulation of 714 
oxytetracycline data in serum using either steady state or single dose (long duration of action) 715 
for computation with application of serum:broth MIC ratio  716 
Computed dose to guarantee average serum 
concentration of кPD-fold MIC for a duration 
of 48h: 
Steady state 
approach 
Single dose 
approach 
Predicted doses for P.multocida 
TAR    
50% 
TAR    
90% 
TAR    
50% 
TAR     
90% 
Bacteriostatic 199.5 423.6 313.7 682.3 
Bactericidal 434.0 921.2 701.2 1523.2 
Predicted doses for M.haemolytica 
TAR    
50% 
TAR    
90% 
TAR     
50% 
TAR     
90% 
Bacteriostatic 125.2 140.6 196.8 283.2 
Bactericidal 180.2 202.6 313.5 451.6 
TAR = target attainment rate (probability for the serum concentration to exceed the PD 717 
endpoint for efficacy). Dosages were computed by Monte Carlo simulation using equations 5 718 
and 8 for steady state and loading dose approaches, respectively, with: (1) Wild Type MIC 719 
distributions ranging from 0.25 to 2μg/mL (n=498) for P.multocida and 0.25-1μg/mL 720 
(n=481) for M.haemolytica determined by the Turnidge method;  (2) average AUC0-721 
24h/MICe)/24h = кPD calculated for experimentally obtained bacteriostatic or bactericidal 722 
action (data from three or four strains) ; (3) individual animal clearance and elimination rate 723 
constant (K10) empirical distributions obtained  for 10 healthy calves (present study) 724 
receiving the dose recommended by the manufacturer (20mg/kg) ; (4) fu the average 725 
oxytetracycline free fraction determined experimentally; and (5) the difference in MIC 726 
broth:serum ratio of 27.4:1 for P.multocida and 25.2:1 for M.haemolytica.   727 
 33 
Figure 1: Mean ± SEM oxytetracycline concentration in serum, exudate and transudate of 728 
calves after intramuscular injection of oxytetracycline at a dose rate of 20mg/kg. 729 
 730 
  731 
 34 
Figure 2: MIC distributions for P.multocida (498 strains, Fig 2.a) and M.haemolytica (481 732 
strains, Fig 2.b). All specimens were collected from infected cattle and MIC measured at the 733 
Iowa state Veterinary Diagnostic Laboratory Data from 2000, 2001, 2002 and 2003 734 
(http://vads.vetmed.vt.edu/index.cfm). The wild type populations were statistically 735 
determined according to Turnidge et al. (2006) to calculate the 99.9th percentile of the 736 
Epidemiological Cut-off (ECOFF). The WT distributions for P.multocida (Fig 2.c) and 737 
M.haemolytica (Fig 2.d) were fitted with a blue curve.  738 
 739 
 740 
 741 
 742 
 743 
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Supplementary data 746 
Appendix 1 747 
PK-PD integration for oxytetracycline in calf serum for P.multocida and M.haemolytica: 748 
mean values (n=10 calves) 749 
 750 
 
Variable (units) 
           P.multocida             M.haemolytica 
Based on  
mean serum 
MIC (6.75 
µg/mL) 
Based on  
mean MHB  
MIC 
(0.25 µg/mL) 
Based on  
mean serum 
MIC (5.46 
µg/mL) 
Based on  
mean MHB 
MIC (0.22 
µg/mL) 
Cmax/MIC 
AUC0-24h/MIC (h) 
AUC0-∞/MIC (h) 
T>MIC (h) 
0.77  
12.97  
24.28  
0  
20.92  
350.1  
655.5  
104.4  
0.96  
16.03  
30.01 
 1.14  
23.77  
397.8  
744.9  
110.5  
 751 
 752 
  753 
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Appendix 2 754 
Predicted dosage (mg/kg) based on PK-PD modelling and Monte Carlo simulation of 755 
oxytetracycline data in MHB using either steady state or single dose (long duration of action) 756 
for computation without application of serum:broth MIC ratio  757 
 758 
Computed dose to guarantee average serum 
concentration of кPD-fold MIC for a duration 
of 48h: 
Steady state 
approach 
Single dose 
approach 
Predicted doses for P.multocida 
TAR 
50% 
TAR 
90% 
TAR 
50% 
TAR 
90% 
Bacteriostatic 7.28 15.46 11.45 24.9 
Bactericidal 15.84 33.62 25.59 55.59 
Predicted doses for M.haemolytica 
TAR 
50% 
TAR 
90% 
TAR 
50% 
TAR 
90% 
Bacteriostatic 4.97 5.58 7.81 11.24 
Bactericidal 7.15 8.04 12.44 17.92 
 759 
TAR = target attainment rate (probability for serum concentration to exceed the PD endpoint 760 
for efficacy). Dosages were computed by Monte Carlo simulation using equations 5 and 8 for 761 
steady state and loading dose approaches, respectively, with: (1) Wild Type MIC distributions 762 
ranging from 0.25 to 2 μg/mL (n=498) for P.multocida and 0.25-1 μg/mL (n=481) for 763 
M.haemolytica determined by the Turnidge (2006) method: (2) average AUC0-24h/MICe)/24h 764 
= кPD calculated for experimentally obtained bacteriostatic, bactericidal action (data from 765 
three or four strains) ; (3) individual animal clearance and elimination rate constant (k10) 766 
empirical distributions obtained  for 10 healthy calves (present study) receiving the dose 767 
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recommended by the manufacturer (20 mg/kg) ; (4) fu the average oxytetracycline free 768 
fraction determined experimentally 769 
 770 
To explore the EUCAST data for MH and PM base follow this link771 
 772 
 773 
 774 
